“ However with out additional change, the prices of recent and highly specialised medicine will seemingly
rise, particularly at a time when pharmaceutical companies are dealing with sluggish revenue
prospects. Can patients access the drugs they want?
Americans even have sooner access to new drugs than patients in lots of different international locations.
In off-patent markets, the competitors is fierce and prices of generic medicine are
low. Generic penetration is high in the U.S. Drug
costs are high in the U.S. That’s because in lots of international locations,
authorities agencies basically regulate the prices of medicines and set limits to the quantity they'll reimburse; they
might solely agree to pay for a drug if they feel that the value is justified by the therapeutic
benefits. This centralized strategy may give them more bargaining power over
drug makers. Where there are competing medicine, insurers enjoy extra bargaining power and will negotiate reductions with
manufacturers in change for lower value-sharing for patients. ”